1. Market Research
  2. > Therapy Industry
  3. > All premium reports
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Publication dates

1-10 of about 2200 reports for phase iii clinical trial

Purchase Reports From Reputable Market Research Publishers

Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast (2016-2022)

Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast (2016-2022)

  • $ 5274
  • Industry report
  • September 2016
  • by Industry ARC

Pharmacovigilance is referred to as a practice of monitoring the effects of medical drugs after they have been licensed for use, especially in order to identify and evaluate previously unreported adverse ...

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

  • $ 4950
  • Industry report
  • May 2016
  • by Grand View Research

Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key ...

Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020

  • $ 5000
  • Industry report
  • December 2015
  • by Future Market Insight Global & Consulting Pvt Ltd

Future Market Insights offers a 6-year forecast of the global pharmacovigilance market between 2015 and 2020. In terms of value, the market is expand at a CAGR of 14.2% during the forecast period. This ...

Blincyto | blinatumomab - Oncology drug report: 2014-2015 analysis; 2016-2021 expectations

Blincyto | blinatumomab - Oncology drug report: 2014-2015 analysis; 2016-2021 expectations

  • $ 300
  • Industry report
  • December 2016
  • by Cancer Research Analytics

“Blincyto: Expensive drug in a niche market” is a comprehensive drug report about one of the most expensive drugs used in the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell ...

Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations

Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations

  • $ 1000
  • Industry report
  • November 2016
  • by Cancer Research Analytics

“Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations” is a comprehensive report on Neupogen and Neulasta, two market leading drugs (by ...

Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

  • $ 500
  • Industry report
  • November 2016
  • by Cancer Research Analytics

Description “Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the fouth-largest oncology drug by 2015 sales. Revlimid is ...

Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations

Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations

  • $ 300
  • Industry report
  • December 2016
  • by Cancer Research Analytics

“Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the most controversial drug in recent times. Iclusig is the first and only ...

Oncology drug report - Vidaza - azacitidine - 2004-2015 analysis; 2016-2021 expectations

Oncology drug report - Vidaza - azacitidine - 2004-2015 analysis; 2016-2021 expectations

  • $ 300
  • Industry report
  • December 2016
  • by Cancer Research Analytics

Vidaza: Top drug losing sheen” is a comprehensive drug report on the largest drug in the MDS space that seems to be falling apart post its patent expiry. Vidaza is the fourth-largest drug in Celgene’s ...

Iressa - gefitinib -Oncology drug report -  2002-2015 analysis; 2016-2021 expectations

Iressa - gefitinib -Oncology drug report - 2002-2015 analysis; 2016-2021 expectations

  • $ 300
  • Industry report
  • December 2016
  • by Cancer Research Analytics

“Iressa: on a downward spiral” is a comprehensive drug report about the first EGFR tyrosine kinase inhibitor drug in the NSCLC market. Iressa is the first drug in the EGFR-TKI market to be approved ...

Gardasil | human papillomavirus vaccine - Oncology drug report: 2006-2016 analysis, 2017-2021 expectations

Gardasil | human papillomavirus vaccine - Oncology drug report: 2006-2016 analysis, 2017-2021 expectations

  • $ 300
  • Industry report
  • January 2017
  • by Cancer Research Analytics

“Gardasil: star cancer vaccine” is a comprehensive drug report on the market leader of HPV vaccine segment (according to 2015 sales). In this report, Gardasil and Gardasil 9 are considered as a single ...

About 4300 reports for phase iii clinical trial

Download Unlimited Documents from Trusted Public Sources

Recro Pharma, Inc. - Company Report, November 2016

  • November 2016
    4 pages
  • Anti Rheumatic  

    Clinical Trial  

    Abdominoplasty  

  • United States  

    World  

View report >

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.